Magazine

COVID-19

Our understanding of COVID-19 has evolved greatly since its first appearance in the U.S. in early 2020. Though our knowledge remains incomplete, we’ve learned a lot about the pathophysiology of the virus—especially its unique effects on the heart.

pgp_ci.jpg

Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?

dt_ci_v2.jpg

Experienced dyad and triad partners share tips for setting the stage for success and putting the brakes on mistakes.

Tom Giangiulio

As many as 700 hearts from donors with hepatitis C are discarded each year in the U.S. New research suggests at least some of these organs may be suitable for transplant.

firstword_cvb.jpg

Even the best analytics won’t replace human interaction; protect your time with patients and colleagues. Focus on the patient-centered metrics, and try to be patient. It takes time to turn a mess into a masterpiece.

data_dilemma-v1.jpg

To get the operational perspective, CVB hosted a roundtable discussion with service line leaders about the opportunities and challenges they encounter around data.
 

ci_2.jpg

Forward-looking providers are converting reams of data from myriad sources into innovative new ways to deliver healthcare and improve efficiencies.

Marijuana use among older adults is associated with a heightened risk of atrial and ventricular arrhythmias, according to new research published in the American Journal of Cardiology. “Marijuana use increases sympathetic nervous system activity and inhibits cardiac parasympathetic innervation, resulting in elevated heart rate, elevated blood pressure, and an increase in myocardial oxygen demand.

As use of cannabis products increases and evidence of possible cardiovascular harm mounts, it’s time for cardiologists to start having conversations with their patients.

ryan_madder_md.jpg

Telehealth enthusiasts are optimistic about telestenting’s potential to solve access-to-care issues but concede that significant obstacles must be overcome before it will be ready for prime time.

heart.jpg

The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist. 

acc19.jpg

Clinical trials presented at ACC.19 flipped the script on TAVR vs. SAVR. 

Christine Albert, MD, MPH

The Heart Rhythm Society's 2019 scientific sessions will be held May 8-11 in San Francisco, a venue that enabled the program committee to tap into Silicon Valley’s expertise with digital health, emerging technology and innovation. HRS.19 Program Director Christine Albert, MD, MPH, gave Cardiovascular Business a preview of meeting highlights.